Related Experiment Video
Updated: Jun 9, 2025

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline
Daniela Melchiorri1, Tamarie Rocke2, Richard A Alm3
1Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy; AMR Division, World Health Organization, Geneva, Switzerland.
Insights
Antimicrobial resistance is a global health crisis, especially impacting young children. This study assesses new antibiotics against priority pathogens to address critical research and development gaps.
Area of Science:
- Microbiology
- Infectious Diseases
- Drug Discovery
Background:
- Antimicrobial resistance (AMR) is a significant global health threat, leading to millions of deaths annually.
- Children under five are particularly vulnerable to AMR-related infections.
- Current antimicrobial research and development (R&D) is insufficient compared to other major diseases.
Purpose of the Study:
- To evaluate the efficacy of current and novel antibiotics against the World Health Organization's (WHO) 2024 bacterial priority pathogens list.
- To identify gaps and guide future R&D efforts in the antibacterial drug pipeline.
- To monitor evolving resistance patterns and emerging resistance mechanisms.
Main Methods:
- Analysis of the global antibacterial clinical pipeline.
- Evaluation of antibiotic activity against the 2024 WHO bacterial priority pathogens.
- Trend analysis of R&D output and innovation potential.
Main Results:
- The study highlights persistent gaps in the development of effective antibacterial drugs.
- Evolving resistance patterns necessitate continuous evaluation of antibiotic efficacy.
- The 2024 WHO priority pathogens list reflects current trends in bacterial infections and resistance.
Conclusions:
- A comprehensive strategy is needed to combat AMR, including robust R&D.
- Continuous monitoring and evaluation of the antibacterial pipeline are crucial.
- Targeted antibiotic development against priority pathogens is essential for global health security.
Abstract:
Antimicrobial resistance continues to evolve and remains a leading cause of death worldwide, with children younger than 5 years being among those at the highest risk. Addressing antimicrobial resistance requires a comprehensive response, including infection prevention efforts, surveillance, stewardship, therapy appropriateness and access, and research and development. However, antimicrobial research and development is limited and lags behind the output of other fields, such as that of cancer or HIV research. The 2023 WHO analysis of the global antibacterial clinical pipeline serves as a tool to monitor and guide research and development efforts. The analysis emphasises the remaining gaps in developing a robust and effective antibacterial drug pipeline, drawing insights from trend analyses and assessment of the innovation potential of candidate antimicrobials. In the present analysis, we evaluated the activity of antibiotics against the new WHO bacterial priority pathogens list 2024, which reflects changing trends in resistance patterns, distribution of bacterial infections, and the emergence of new resistance mechanisms.
More Related Videos
08:58Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes
Published on: March 3, 2023
05:57Author Spotlight: Exploring Cytoskeletal Dynamics to Unveil Novel Antibiotics Through Innovative Cell-Based Assays
Published on: April 26, 2024
Related Concept Videos
Development of Antibiotic Resistance
Antibiotic Selection
Microorganisms in Medicine and Therapeutics
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Gene Regulation in Microbial Communities: Quorum Sensing